Groundbreaking Cambridge research indicates immunosuppression may help treat Parkinson’s
A pioneering trial, led from Cambridge Biomedical Research Centre, has shown that immunosuppressing medicines could provide the key to treatment of Parkinson's disease, according to results presented this weekend at the world's most prestigious neurodegeneration conference AD/PD
The AZA/PD trial which was carried out at the NIHR Cambridge Clinical Research Facility is the first show that broadly suppressing the immune system could have a beneficial impact in Parkinson's disease.
Participants on the treatment reported an overall improvement in movement-related symptoms. This means they found it easier to perform tasks such as moving around, writing, washing and dressing.
These improvements were greater in female participants compared to males.
Additionally, patients with faster-progressing Parkinson's disease showed signs of improved memory and thinking skills. Importantly, the trial did not reveal significant safety concerns around using immunosuppression treatment in Parkinson's disease. This will enable larger research studies of immune therapies for PD in the future.
For full article visit: CUH News
Latest from CCTU
National Patient Led Research Hub celebrates tenth anniversary
A national team based in Cambridge are celebrating ten years of helping people living with rare diseases to develop their own research ideas. The hub has…
Hope for MS patients as Cambridge trial suggests drug combination may repair nerve damage
Early findings from a clinical trial in Cambridge suggest a combination of metformin, a diabetes drug, and clemastine, an antihistamine, can help repair…
Prospective study into controversial brain cyst syndrome is world first
The world’s first study of its kind highlights the potential value of surgery to treat a specific kind of brain cyst that blights the lives of patients.
